CAS 857890-39-2 Pharmaceutical Raw Materials Lenvatinib Mesylate E7080 Powder for Thyroid Cancer
Product Name: lenvatinib Mesylate
Cas No.: 857890-39-2
Molecular Weight: 236.65
Single impurity: ≤0.5%
Residue on ignition: ≤0.5%
Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. Lenvatinib is used for your treatment of differentiated thyroid cancer which is either locally recurrent ormetastatic, progressive, and would not respond to treatment with radioactive iodine (radioiodine).LENVATINIB is a medicine that targets proteins in cancer cells and stops the cells of cancer from growing. It can be used to treat thyroid cancer and kidney cancer. Compare kinase inhibitors.
How Lenvatinib works:
This medication is utilized to treat kidney or thyroid cancer. Lenvatinib is owned by a class of medicine known as tyrosine kinase inhibitors. It functions by slowing or stopping the development of cancer cells.
Purposes of Lenvatinib:
Lenvatinib is a prescription drugs used to treat people with differentiatedthyroid cancer (DTC, a form of thyroid cancer) that can no longer be treated with radioactive iodine and is progressing.
Lenvima is additionally used in combination with everolimus in patients with advanced renal cell carcinoma who had previously received an anti-angiogenic therapy.
Medicines may be prescribed for other uses. Ask a medical expert or pharmacist to learn more.
Where can i store this drug?
Keep out of the reach of youngsters.
Store between 20 and 25 degrees C (68 and 77 degrees F). Get rid of any unused medicine as soon as the expiration date.